<DOC>
	<DOCNO>NCT00000400</DOCNO>
	<brief_summary>This study look effect two medication , alendronate parathyroid hormone , bone mass bone formation bone breakdown woman osteoporosis . We randomly select postmenopausal woman osteoporosis receive laboratory-produced human parathyroid hormone ( hPTH ) , alendronate , 2.5 year . Study participant return study center periodically bone mass measure give blood urine sample test bone formation breakdown laboratory test . Those complete study eligible one two 12 month extension study .</brief_summary>
	<brief_title>Alendronate and/or Parathyroid Hormone Osteoporosis</brief_title>
	<detailed_description>This randomize , prospective , open-label study osteoporotic postmenopausal woman self-administer synthetic hPTH- ( 1-34 ) , alendronate , , every day 2.5 year . Participants initially come Massachusetts General Hospital month , subsequently every 3-6 month , measurement serum urine index bone formation resorption , serum urine toxicity test , DXA/QCT measurements bone mass . One-third participant take hPTH- ( 1-34 ) daily , one-third take alendronate daily , one-third take daily ( Phase A , month 0-30 ) . Participants complete Phase A eligible 12 month extension study ( Phase B , month 30-42 ) , alendronate treatment continue without change hPTH 1-34 treatment stop . Participants complete Phase B eligible second 12 month extension study ( Phase C , month 42-54 ) , alendronate treatment continue without change every participant take hPTH 1-34 . During Phases B C , participant come Massachusetts General Hospital every 6 month measurement serum urine index bone formation resorption , serum urine toxicity test , DXA/QCT measurements bone mass .</detailed_description>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Alendronate</mesh_term>
	<mesh_term>Teriparatide</mesh_term>
	<criteria>Lumbar spine hip BMD Tscore less equal minus 2.0 Postmenopausal least 5 year Fully ambulatory Able give inform consent No concurrent illnesses cause bone loss No recent drug treatment osteoporosis No recent fracture</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Osteoporosis</keyword>
	<keyword>Bone formation</keyword>
	<keyword>Bone resorption</keyword>
	<keyword>Parathyroid hormone ( PTH )</keyword>
	<keyword>Postmenopause</keyword>
</DOC>